Article
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.
British journal of cancer - 24 Aug 2010
Veltman J D, Lambers M E H, van Nimwegen M, Hendriks R W, Hoogsteden H C, Hegmans J P J J, Aerts J G J V
Abstract excerpt
BACKGROUND: Suppressive immune cells present in tumour microenvironments are known to augment tumour growth and hamper efficacy of antitumour therapies. The amino-bisphosphonate Zoledronic acid (ZA) is considered as an antitumour agent, as recent studies showed that ZA prolongs disease-free survival in cancer patients. The exact mechanism is a topic of debate; it has been suggested that ZA targets...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.